PMID- 37354029
OWN - NLM
STAT- MEDLINE
DCOM- 20231127
LR  - 20231127
IS  - 1472-8206 (Electronic)
IS  - 0767-3981 (Linking)
VI  - 37
IP  - 6
DP  - 2023 Dec
TI  - Tylophora indica (Burm. f.) Merr alleviates tracheal smooth muscle 
      hyperresponsiveness in ovalbumin-induced allergic-asthma model in guinea-pigs: 
      Evidences from ex vivo, in silico and in vivo studies.
PG  - 1153-1169
LID - 10.1111/fcp.12927 [doi]
AB  - BACKGROUND: Tylophora indica (Burm. f.) Merr is a climbing perennial plant 
      reported in Indian traditional system of medicine for its use in allergy and 
      asthma. However, only few scientific studies have been performed in the past to 
      validate its antiasthmatic potential. OBJECTIVES: The present study deals with 
      investigation of airway smooth muscle relaxant and antiasthmatic potential of 
      extract and subsequent fractions prepared from T. indica. METHODS: The most 
      active fraction of T. indica leaves selected through bio-guided activity was 
      subjected to liquid chromatography-mass spectrometry (LC-MS) analysis for 
      chemical profiling. The binding affinity of identified compounds in fraction 
      towards M(3) and H(1) receptors was determined by molecular docking study. F-2 
      (chloroform fraction prepared from methanolic extract of T. indica leaves) was 
      examined for its smooth muscle relaxant properties using isolated trachea of 
      guinea-pig. Further, F-2 was evaluated through in vivo studies employing 
      ovalbumin-induced asthma model in guinea-pigs. RESULTS: F-2 was found most 
      effective in bioassay-guided fractionation. Characterization by LC-MS analysis 
      revealed presence of five major bioactive compounds in F-2 that showed good 
      docking interactions with M(3) and H(1) receptors. The ex vivo study demonstrated 
      that F-2 could significantly relax tracheal rings via targeting multiple 
      signalling pathways videlicet, namely, noncompetitive antagonism of the histamine 
      and muscarinic receptors, beta2-adrenergic stimulation and activation of soluble 
      guanylyl cyclase. In in vivo studies, F-2 ameliorated airway hyperresponsiveness 
      and decreased broncho alveolar lavage fluid (BALF) levels of inflammatory 
      cytokines and immunoglobulin E (IgE). CONCLUSION: These results confirm the 
      traditional use of T. indica as an antiasthmatic agent which are evidenced 
      through ex vivo, in silico and in vivo studies.
CI  - (c) 2023 Societe Francaise de Pharmacologie et de Therapeutique. Published by John 
      Wiley & Sons Ltd.
FAU - Gururani, Ritika
AU  - Gururani R
AD  - Department of Pharmacy, Banasthali Vidyapith, Banasthali, India.
FAU - Patel, Saraswati
AU  - Patel S
AD  - Department of Pharmacy, Banasthali Vidyapith, Banasthali, India.
FAU - Bisht, Akansha
AU  - Bisht A
AD  - Department of Pharmacy, Banasthali Vidyapith, Banasthali, India.
FAU - Jain, Smita
AU  - Jain S
AD  - Department of Pharmacy, Banasthali Vidyapith, Banasthali, India.
FAU - Paliwal, Sarvesh
AU  - Paliwal S
AD  - Department of Pharmacy, Banasthali Vidyapith, Banasthali, India.
FAU - Dwivedi, Jaya
AU  - Dwivedi J
AUID- ORCID: 0000-0002-1524-7714
AD  - Department of Chemistry, Banasthali Vidyapith, Banasthali, India.
FAU - Sharma, Swapnil
AU  - Sharma S
AUID- ORCID: 0000-0003-2639-7096
AD  - Department of Pharmacy, Banasthali Vidyapith, Banasthali, India.
LA  - eng
PT  - Journal Article
DEP - 20230624
PL  - England
TA  - Fundam Clin Pharmacol
JT  - Fundamental & clinical pharmacology
JID - 8710411
RN  - 9006-59-1 (Ovalbumin)
RN  - 0 (Anti-Asthmatic Agents)
SB  - IM
MH  - Animals
MH  - Guinea Pigs
MH  - Ovalbumin
MH  - Tylophora
MH  - Molecular Docking Simulation
MH  - *Asthma/drug therapy/chemically induced
MH  - Muscle, Smooth/physiology
MH  - *Anti-Asthmatic Agents/pharmacology
MH  - Trachea/physiology
OTO - NOTNLM
OT  - H1 receptor
OT  - M3 receptor
OT  - asthma
OT  - molecular docking
OT  - tracheal smooth muscle relaxant
EDAT- 2023/06/24 11:42
MHDA- 2023/11/27 12:42
CRDT- 2023/06/24 05:33
PHST- 2023/05/23 00:00 [revised]
PHST- 2022/12/30 00:00 [received]
PHST- 2023/06/05 00:00 [accepted]
PHST- 2023/11/27 12:42 [medline]
PHST- 2023/06/24 11:42 [pubmed]
PHST- 2023/06/24 05:33 [entrez]
AID - 10.1111/fcp.12927 [doi]
PST - ppublish
SO  - Fundam Clin Pharmacol. 2023 Dec;37(6):1153-1169. doi: 10.1111/fcp.12927. Epub 
      2023 Jun 24.